Drug details

Pemazyre (pemigatinib tablets)

type of FGFR Inhibitors

Pemazyre (pemigatinib) is a kinase inhibitor used to treat adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

The following drugs are related to Pemazyre, either as a replacement or used together:

• Adriamycin PFS (doxorubicin hydrochloride)
• Adstiladrin (nadofaragene firadenovec-vncg suspension, for intravesical use)
• Paraplatin (carboplatin)
• Leukeran (chlorambucil)
• Cosmegen (dactinomycin for injection)
• VePesid (etoposide)
• Toposar (etoposide injection)
• Lytgobi (futibatinib tablets)
• Hycamtin (topotecan hydrochloride)
• Hycamtin Capsules (topotecan capsules)
• Ifex (ifosfamide)
• Truseltiq (infigratinib capsules)
• Tepadina (thiotepa for injection)
• Thiotepa (thiotepa injection)